European journal of preventive cardiology
Future myocardial infarction after an acute coronary syndrome and pharmacogenetic response to dalcetrapib.
Jean-Claude Tardif, Marc A Pfeffer, Simon Kouz, Wolfgang Koenig, Aldo P Maggioni, John J V McMurray, David D Waters, J Wouter Jukema, Harvey D White, Therese Heinonen, David Kallend, Fouzia Laghrissi-Thode, Valtteri Muroke, Annik Fortier, Marie-Claude Guertin
Published: 202510.1093/eurjpc/zwaf661
Abstract
BACKGROUND: Acute coronary syndrome (ACS) survivors have heightened risk for subsequent cardiovascular events. METHODS: All baseline characteristics collected in both the Dal-Outcomes and Dal-GenE trials were considered as potential risk markers. A p…
Preview only. Read the full abstract at the source